DataMeds AI, Inc.
MEDS Nasdaq· Wholesale-Drugs, Proprietaries & Druggists' Sundries
Last close · Oct 26, 2026
$2.19
KIRA · Stoqly’s AI analyst, in plain words
- DataMeds AI, Inc. had $23.3M of revenue in fiscal 2025, up 28.7% on the year before.
- Its operating margin was −401.7%, down 367.8 pts: of every 100 in sales, about −402 is left after running the business.
- DataMeds AI, Inc. lost $101M in fiscal 2025.
- DataMeds AI, Inc. owes $34.3M more than it holds in cash.
Market cap
$5.6M
P/E
—
Revenue
$23.3M
Net income
−$101M
Free cash flow
—
Operating margin
−401.7%
DataMeds AI, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+28.7%
Yes. Sales grew 28.7% last year.
Does it make a profit?
−433.9%
No. It lost money last year.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What DataMeds AI, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 20, 2026
- Legal name
- DataMeds AI, Inc.
- CIK
- 0002030763
DataMeds AI, Inc. · MEDS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | $18.1M | $23.3M |
| Revenue growth | — | — | 28.7% |
| Gross margin | — | 9.7% | −27.5% |
| Operating margin | — | −33.9% | −401.7% |
| Net income | −$2.9M | −$6.9M | −$101M |
| Net margin | — | −37.8% | −433.9% |
| Diluted EPS | −$0.06 | −$0.15 | −$1.43 |
| Cash | |||
| Cash from operations | −$0.3M | −$1.2M | −$10.9M |
| Share count change | — | 5.7% | 50.2% |
| Debt and strength | |||
| Cash and short-term investments | $0.0M | $1.0M | $0.0M |
| Debt incl. finance leases | $0.4M | $35.3M | $34.4M |
| Shareholders' equity | −$2.9M | $6.7M | −$12.4M |
| Current ratio | 0.1x | 0.4x | 0.1x |
| Interest coverage | −190.8x | −7.4x | −20.5x |
| Returns and quality | |||
| Return on capital | — | −11.8% | −338.4% |
| Return on equity | — | −357.7% | — |
| Piotroski F-score | — | 4 | 2 |
| Altman Z'' | −135.5 | −3.8 | −38.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
DataMeds AI, Inc. · MEDS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.19 a share, the company is worth $5.6M.
Source: SEC EDGAR XBRL filings (CIK 0002030763). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.